Company / R&D per Share
TherapeuticsMD, Inc. R&D per Share History
FY2015-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.07
FY2021
5-year range
$0.07 / $0.10
FY2017-FY2021
Trend
-34.4%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share has declined for 4 consecutive years, from $0.37 in FY2017 to $0.07 in FY2021.
Based on SEC 10-K filings.
0.07 in FY2021 with a 5-year CAGR of -22.9%.
Declined from $0.14 to $0.07 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -35.8%
- 5-Year CAGR
- -22.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- TherapeuticsMD, Inc.'s r&d per share has declined for 4 consecutive years.
- In FY2021, r&d per share decreased 34.4% year-over-year.
- Peak r&d per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $0.07 | -34.4% |
| FY2020 | $0.10 | -28.5% |
| FY2019 | $0.14 | -43.5% |
| FY2018 | $0.25 | -32.0% |
| FY2017 | $0.37 | +50.8% |
| FY2016 | $0.24 | +159.9% |
| FY2015 | $0.09 | +201.7% |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026